Fate Therapeutics to Present at Upcoming March Investor Conferences

On March 1, 2024 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, reported that the Company will participate in the following upcoming investor conferences (Press release, Fate Therapeutics, MAR 1, 2024, View Source [SID1234640696]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th, 2024 at 9:10 AM ET in Boston, Massachusetts

Participating in an industry panel and hosting 1×1 investor meetings
Leerink Global Biopharma Conference on Monday, March 11th, 2024 at 2:00 PM ET in Miami, Florida

Participating in a fireside chat and hosting 1×1 investor meetings
Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12th, 2024 at 11:15 AM ET in Miami, Florida

Participating in a fireside chat and hosting 1×1 investor meetings
Jefferies Biotech on the Bay Summit on Wednesday, March 13th, 2024 in Miami, Florida

Hosting 1×1 investor meetings
2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 3:00 PM ET

Participating in a fireside chat
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.